FDA panel recommends Novartis’s bronchodilator

An advisory panel of the US Food and Drug Administration has recommended approval of Novartis’s indacaterol as the first once-daily, long-term maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease.